Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14

3 Mar 2020

Abstract excerpt

, CD79B mutant (MCD) genetic subtype of diffuse large B cell lymphoma (DLBCL), which relies on B cell receptor (BCR) signaling for survival. However, the pathogenic role of KLHL14 in DLBCL and its molecular function are largely unknown. Here, we report that KLHL14 is in close proximity to the BCR in the endoplasmic reticulum of MCD cell line models and promotes the turnover of immature glycoforms of BCR subunits,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32127472
DOI: 10.1073/pnas.1921187117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14PMID 32127472Read ↗

Pathogenic B‐cell receptor signaling in lymphoid malignancies: New insights to improve treatmentSemantic proximity Read ↗

A multiprotein supercomplex controlling oncogenic signalling in lymphoma.Semantic proximity Read ↗

Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma.Semantic proximity Read ↗

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sitesSemantic proximity Read ↗

MYD88 <sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapySemantic proximity Read ↗

MYD88 gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies.Semantic proximity Read ↗

Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical PracticeSemantic proximity Read ↗

An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma.Semantic proximity Read ↗

Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behaviorSemantic proximity Read ↗

B-cell receptor signaling as a driver of lymphoma development and evolution.Semantic proximity Read ↗

B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells.Semantic proximity Read ↗

Inhibition of autoantigen-induced B-cell receptor (BCR) internalization as a therapeutic strategy in Diffuse Large B Cell Lymphoma (DLBCL)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.